分子靶向药物在肝细胞癌治疗中的临床研究进展

肝癌是全球第六大常见的恶性肿瘤，也是第四大肿瘤相关死亡原因，其中肝细胞癌（hepatocellular carcinoma，HCC）占90%，且80%以上的HCC发生在肝炎和肝硬化等患者中。对于HCC的治疗方面，仅20%的HCC患者可进行手术切除、肝脏移植或射频消融治疗，而晚期HCC患者无法进行根治性治疗，其生存率也逐渐下降。近年来，分子靶向药物治疗已成为研究热点，该类药物可通过特异性的与致癌位点靶向结合而发挥抗癌作用。目前，抗HCC的靶向药物主要分为一线药物与二线药物，其中一线药物主要包括索拉非尼、仑伐替尼，二线药物主要包括瑞戈非尼、卡博替尼及雷莫芦单抗等。本文对此类分子靶向药物在HCC治疗中的临床研究进展进行综述。 

Clinical research progress of molecular targeted drugs in treatment of hepatocellular carcinoma

Liver cancer ranks the sixth in most common malignant tumor and the fourth in leading cause of tumor-related death worldwide, of which hepatocellular carcinoma (hepatocellular carcinoma, HCC) accounts for 90%. More than 80% of HCC occurs in patients with hepatitis and cirrhosis. And only 20% of HCC patients can be treated with surgical resection, liver transplantation or radiofrequency ablation, while the patients with advanced HCC can not receive radical treatment, so their survival rate is low. In recent years, molecular targeted drug therapy has become a research hotspot, and the drug can exert its anticancer effect by specifically binding to carcinogenic sites. At present, the targeting drugs of anti-HCC are mainly divided into first-line drugs and second-line drugs, of which the first-line drugs mainly include sorafenib and lenvatinib, and the second-line drugs mainly include regofinib, carbotinib and ramoruximab.